Idiopathic Intracranial Hypertension (Pseudotumor Cerebri)

Idiopathic intracranial hypertension (IIH), formerly called pseudotumor cerebri, is a condition of elevated pressure inside the skull without an identifiable cause like a tumor or blood clot. The increased pressure can damage the optic nerves and cause vision loss if untreated.

After urgent vision concerns have been addressed, neuro-ophthalmology follow-up or a second opinion can support long-term vision monitoring.

Complete IIH Treatment Guide

For a step-by-step comparison of weight management, medication, vision monitoring, and surgery, see IIH Treatment and Long-Term Management.

Understanding IIH

IIH is thought to involve abnormal CSF pressure regulation, venous outflow, and metabolic or hormonal factors. The exact mechanism remains under study. The resulting pressure can affect the brain and particularly the optic nerves where they enter the skull.

The condition is called:

• Idiopathic: no identified cause
• Intracranial hypertension: high pressure inside the skull
• Pseudotumor cerebri: old name meaning "false brain tumor" (mimics tumor symptoms)
• Benign intracranial hypertension (BIH): an older name now used less often because untreated IIH can permanently damage vision

How Serious Is IIH, and Can IIH Kill You?

IIH itself is usually not fatal. Its main medical danger is permanent vision loss from ongoing pressure on the optic nerves. Headaches, pulsatile tinnitus, double vision, fatigue, and cognitive symptoms can also have a major effect on daily life even when central vision remains clear.

Urgent symptoms still matter because a sudden severe headache, fainting, seizure, confusion, weakness, speech difficulty, or a rapid vision change may signal a complication or a different emergency. Call 911 for those symptoms. A clear decline in vision with known IIH needs same-day emergency assessment because optic nerve damage can progress quickly.

Symptoms

Headache

• Most common symptom
• Often daily, throbbing
• Worse in morning
• Worse with straining, coughing, bending
• May improve after vomiting
• May be triggered by lying down

Visual Symptoms

• Transient visual obscurations: brief (seconds) dimming or graying of vision
• Often triggered by position change or straining
• Visual field loss: may be gradual and unnoticed
• Blurred vision
• Double vision: from sixth nerve palsy

Other Symptoms

• Pulsatile tinnitus: whooshing sound in ears synchronized with heartbeat
• Neck and shoulder pain
• Nausea
• Cognitive difficulties ("brain fog")

Who Gets IIH?

Classic Demographic

• Women of childbearing age (15-44 years)
• Overweight or recent weight gain
• 20 times more common in obese women
• Can occur in men and children (less common)

Associated Factors

• Obesity (most important risk factor)
• Recent weight gain
• Certain medications (tetracyclines, vitamin A/retinoids, growth hormone)
• Venous sinus stenosis (narrowing)
• Sleep apnea

Diagnosis

Fundoscopic Examination

• Papilledema: swelling of the optic discs
• Key finding that raises suspicion for IIH
• Severity correlates with risk of vision loss

Visual Field Testing

• Detects vision loss that patient may not notice
• Often shows enlarged blind spot
• May show peripheral constriction
• Essential for monitoring

Brain Imaging

• MRI brain with MRV: required to rule out other causes
• May show: empty sella, flattened back of eyeballs, enlarged optic nerve sheaths, venous sinus stenosis
• Rules out tumors, blood clots, other structural causes

Lumbar Puncture (Spinal Tap)

• Documents elevated opening pressure: typically >25 cm H2O (often higher)
• CSF composition is normal
• May provide temporary relief of symptoms
• Usually required for diagnosis unless a specialist determines a different approach is needed because of safety or clinical context

Optical Coherence Tomography (OCT)

• Measures optic nerve fiber layer thickness
• Tracks papilledema over time
• Detects early nerve damage

Diagnostic Criteria (Modified Dandy)

1. Symptoms of elevated intracranial pressure (headache, vision symptoms)
2. Papilledema present
3. Normal neurological exam (except cranial nerve VI palsy)
4. Normal brain imaging (MRI/MRV)
5. Elevated CSF pressure on lumbar puncture
6. Normal CSF composition

Are There 4 Stages of Intracranial Hypertension?

There is no universal four-stage system for IIH. Some hospitals and research groups use local severity categories, so a stage number from one source may have a different meaning elsewhere.

Clinicians commonly grade papilledema with the Frisén scale from 0 to 5. They also assess visual acuity, color vision, visual fields, OCT findings, symptoms, and whether vision is stable or worsening. These measurements are more useful for treatment decisions than a generic four-stage label. The visual field image above shows examples of possible progression; it is not an official staging system.

IIH Treatment

Weight Loss

• A major long-term treatment
• 5-10% weight loss can significantly improve symptoms
• Can improve or sometimes resolve papilledema and symptoms, especially when sustained; ongoing monitoring is still needed
• Bariatric surgery may be considered for severe obesity

Medications

Acetazolamide (Diamox)

• First-line medication
• Reduces CSF production
• Start low, increase gradually
• Side effects: tingling, carbonated drinks taste flat, kidney stones

Topiramate (Topamax)

• Alternative or addition to acetazolamide
• May help with headache
• Can cause weight loss (advantage in IIH)
• Side effects: cognitive slowing, tingling

Furosemide

• Sometimes added to acetazolamide
• Monitor potassium

GLP-1 Receptor Agonists (Emerging Treatment)

GLP-1 medications (such as semaglutide, sold as Ozempic or Wegovy) are showing significant promise for IIH. GLP-1 agonists may support IIH care through two pathways:

1. Weight loss - a major long-term treatment for IIH
2. Possible CSF pressure effects - GLP-1 receptors on the choroid plexus (where CSF is made) may reduce fluid secretion independent of weight loss

The IIH Pressure Trial (Brain, 2023) found that exenatide lowered intracranial pressure within hours of the first dose. Headache days improved numerically more with exenatide than placebo. The small trial was underpowered for definitive headache conclusions. A large retrospective study in JAMA Neurology (2025) identified more than 44,000 IIH patients and then compared matched cohorts; GLP-1 use was associated with lower rates of papilledema, headache, and visual disturbances. Observational data cannot prove causation.

GLP-1 medications are not yet standard of care for IIH, and more research is needed. For a detailed review of the evidence, see our guide on GLP-1 medications and eye health.

Procedures

Serial lumbar punctures

• Repeated lumbar punctures are not recommended for routine IIH treatment because pressure relief is short-lived
• When vision is imminently threatened, specialists may occasionally use temporary CSF drainage, including serial lumbar punctures in selected situations such as pregnancy, while arranging definitive treatment
• This is an urgent specialist decision, not a routine bridge while medication takes effect

Surgery (for severe or progressive cases)

Optic nerve sheath fenestration

• Creates window in optic nerve covering
• Protects vision
• May not help headache

Shunting procedures

• Ventriculoperitoneal (VP) shunt or lumboperitoneal shunt
• Drains excess CSF and is used primarily to protect vision when visual function is deteriorating
• Headache may persist or recur despite pressure control; shunting is generally not recommended for headache alone
• May need revision over time

Venous sinus stenting

• For patients with venous sinus stenosis
• May reduce pressure
• Specialized centers

Monitoring

Regular follow-up is essential:

• Visual field testing: every few months or more often if unstable
• OCT: tracks nerve fiber layer
• Clinical exam: checking papilledema
• Symptom assessment
• Weight monitoring

When to Go to the ER for IIH

Is IIH Curable? Prognosis and Remission

IIH can go into remission, which means papilledema and pressure-related symptoms remain controlled and active treatment may no longer be needed. Clinicians usually use the word remission because IIH can return, especially after weight regain. Some people have a single episode, while others need long-term treatment or experience recurrences.

Good Outcomes

• Many patients do well with timely diagnosis, treatment, and close follow-up
• Symptoms often improve or resolve
• Weight loss can lead to long-term remission

Concerns

• Without treatment, progressive vision loss can occur
• Vision loss may be permanent
• May recur, especially with weight regain
• Requires ongoing monitoring

Is IIH a Disability?

IIH can be disabling when chronic headaches, visual field loss, double vision, pulsatile tinnitus, fatigue, or cognitive symptoms substantially limit work, school, driving, or daily activities. The diagnosis alone does not determine eligibility for workplace accommodations or disability benefits. Eligibility depends on documented functional limitations and the rules of the employer, insurer, or government program.

Useful documentation may include visual field and OCT results, headache frequency, medication side effects, driving restrictions, missed work, and specific tasks that symptoms make difficult. Possible workplace or school accommodations include flexible scheduling, screen breaks, reduced glare, remote work, transportation support, or medical leave. Ask your clinician to document how IIH affects your function, then review the applicable process with human resources, a disability coordinator, or a qualified benefits adviser.

Frequently Asked Questions

Is IIH the same as a brain tumor?

No. The old name "pseudotumor cerebri" meant it mimics tumor symptoms, but there's no actual tumor. IIH is caused by elevated CSF pressure without a structural cause.

Will I go blind from IIH?

Without treatment, progressive vision loss can occur. However, with proper monitoring and treatment, most people maintain good vision. This is why regular visual field testing is so important.

Do I have to lose weight?

Weight loss is the most effective long-term treatment for IIH in overweight patients. Even modest weight loss (5-10%) can significantly improve the condition. Medications can help but work best combined with weight management.

Why do I have double vision?

The elevated pressure can stretch the sixth cranial nerve, which controls outward eye movement. This is usually temporary and improves as pressure is controlled.

How long do I need to take medication?

It varies. Some people can taper off after weight loss and stabilization. Others need long-term treatment. Your doctor will guide tapering based on your response.

What does an IIH headache feel like?

IIH headaches may be daily, positional, or migraine-like. They can be worse in the morning or when lying down and may worsen with straining, coughing, or bending. Associated visual symptoms, papilledema, and pressure findings help distinguish IIH from migraine and other headache disorders.

Can I exercise with IIH?

Yes, regular exercise is generally safe and encouraged because it supports weight loss, the most effective long-term treatment for IIH. Light to moderate aerobic exercise (walking, swimming, cycling) is ideal. However, avoid heavy Valsalva maneuvers such as straining during heavy weightlifting, as these can transiently raise intracranial pressure. Listen to your body and discuss an exercise plan with your doctor.

Does IIH cause brain fog or cognitive problems?

Yes. Many IIH patients report cognitive difficulties including problems with concentration, memory, and mental processing speed. Research has documented these cognitive effects, and they can significantly impact daily life and work. The good news is that cognitive symptoms often improve as intracranial pressure is brought under control with treatment and weight loss.

Can IIH come back after treatment?

Yes. Recurrence rates range from 23 to 38% in studies, and weight regain is the most common trigger. This is why maintaining a healthy weight after achieving remission is so important. Continued monitoring, including periodic visual field testing and eye exams, is recommended even after stopping medication, so any recurrence can be caught early before vision is affected.

What is pulsatile tinnitus and is it related to IIH?

Pulsatile tinnitus is a rhythmic whooshing or pulsing sound in one or both ears that synchronizes with your heartbeat. It is caused by turbulent blood flow near the ear, which becomes audible when intracranial pressure is elevated. Pulsatile tinnitus is one of the hallmark symptoms of IIH and often improves as pressure is lowered with treatment. If you develop pulsatile tinnitus, it should be evaluated by a doctor.

Are GLP-1 medications like Ozempic being used to treat IIH?

GLP-1 receptor agonists are emerging as a promising treatment for IIH, with early evidence that they may reduce intracranial pressure through weight loss and direct effects on CSF production. The IIH Pressure Trial showed rapid intracranial-pressure reduction with exenatide. Its headache results were encouraging and underpowered. A large 2025 observational study found better outcomes in matched GLP-1 users. Its design cannot prove causation. These medications are not yet standard of care for IIH. Learn more in our comprehensive guide to GLP-1 medications and eye health.

References

1. Mollan SP, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89(10):1088-1100. See questions 7, 15, and 21 for serial lumbar punctures, shunting for headache, and pregnancy.
2. Friedman DI, et al. Diagnostic criteria for idiopathic intracranial hypertension. Neurology. 2013;81(13):1159-1165.
3. Mitchell JL, et al. The effect of GLP-1 receptor agonist exenatide on intracranial pressure and headache in idiopathic intracranial hypertension. Brain. 2023;146(5):1821-1831.
4. Sioutas GS, et al. GLP-1 receptor agonists in idiopathic intracranial hypertension. JAMA Neurol. 2025;82(9):887-894.
5. North American Neuro-Ophthalmology Society. Idiopathic Intracranial Hypertension.
6. MedlinePlus. Pseudotumor Cerebri.
7. NHS. Intracranial Hypertension.